Lung disease is a global health challenge. Conditions like COPD, emphysema, and lung cancer affect hundreds of millions of people worldwide, yet many patients are still being diagnosed too late. Traditional imaging has focused on structure: identifying nodules, masses, or obvious tissue changes. In 2026, the field is rapidly evolving toward functional insights, understanding not only what the lungs look like but also how they function, region by region. Recent research, industry debate, and major investment activity all point to a pivotal moment in pulmonary imaging.
A Turning Point in Lung Imaging Research
A 2025 study published in JAMA Network Open highlights a striking limitation of current lung cancer screening criteria: most individuals who eventually develop lung cancer are not captured by traditional eligibility definitions that rely on age and smoking history. The researchers propose broader, age-based CT screening strategies that could improve early detection across a more diverse population, including women and never-smokers. This has sparked intense discussion about how we define risk and how imaging can help identify disease earlier. The JAMA Network Open findings on lung cancer screening eligibility underscore a major trend: redefining who is eligible for screening and how much we rely on anatomical criteria alone.
The Journal of the American College of Radiology (JACR) has curated a special issue examining advances in lung imaging and the appropriateness of CT use. These discussions center on the use of advanced imaging in ways that balance early detection with responsible resource use. These developments reflect a growing recognition that lung imaging must expand beyond traditional boundaries, both in who is screened and in what imaging can reveal. With broader eligibility recommendations on the table, CT imaging will increasingly serve as both a structural and functional assessment tool, helping clinicians detect disease earlier and in a wider patient population.
Functional CT Is Becoming Clinically Mainstream
Chest CT has long been a go-to tool for lung imaging, but today’s clinicians increasingly prioritize functional information. Factors such as ventilation and tissue density can reveal disease processes long before gross structural changes appear.
Emerging research supports this shift, showing that regional functional abnormalities often precede detectable structural damage. Functional imaging enables clinicians to visualize how air moves through the lungs, identify density abnormalities that suggest early emphysema, and monitor how these changes progress over time. This evolution reflects a broader trend in radiology: from qualitative interpretation to quantitative, data-driven insight.
Quantitative Data Drive Decision-Making
Clinicians and care teams seek metrics that can be tracked longitudinally, correlated with clinical outcomes, and integrated into treatment planning. Functional CT is uniquely positioned to deliver this kind of data:
- Regional ventilation scores
- Low-density lung quantification
- Functional heterogeneity maps
These data sets enhance how providers monitor disease progression, assess therapeutic response, and personalize interventions without additional radiation or new scanning hardware.
Integrated Functional Imaging Without Workflow Disruption
Technologies that require new scanners, complex protocols, or burdensome workflows struggle to gain traction. The most impactful tools of 2026 meet clinicians where they already are: routine chest CT exams. Functional analytics that integrate into existing workflows without additional hardware, radiation exposure, or workflow disruption are becoming clinical mainstays.
Adding real momentum to these trends is a major announcement from 4DMedical; the company has secured US$100 million in funding to accelerate its U.S. expansion and increase technology dominance in software-based lung imaging.
This investment, one of the largest in software-driven pulmonary imaging, reflects the growing confidence among investors and healthcare leaders in functional imaging’s potential to transform care. The funding will support the expansion of clinical adoption, product development, and broader integration across healthcare systems.
It’s not just validation of 4DMedical’s technology — it’s a signal that the industry is ready to invest in the future of functional lung imaging.
In 2026, lung imaging is no longer just about detecting what’s visible. It’s about extracting the full clinical value from every scan. There is a real possibility to transform how we understand and manage lung disease.